<p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
<p>在 Google 上添加</p>
<p><strong><em>多发性骨髓瘤是一种复杂且无法治愈的血癌，其特征是持续的复发循环和逐渐缩短的缓解期</em></strong></p>
<p><strong><em>活动突显了多发性骨髓瘤未满足的需求</em> <em>以及像 CELMoD 研究这样的新科学，给患者及其亲人带来了希望</em></strong></p>
<p>新泽西州普林斯顿 --（商业资讯）-- 百时美施贵宝（NYSE: BMY）今天宣布与获奖演员、导演、制片人和倡导者 Mariska Hargitay 合作推出 “调查骨髓瘤” 多发性骨髓瘤意识活动。该活动强调了在多发性骨髓瘤中持续科学研究的重要性，包括由 BMS 主导的 CELMoD 研究，这是一种被定义为 cereblon E3 连接酶调节的研究。CELMoD 研究专注于参与疾病的关键蛋白质，以便通过细胞自身的蛋白质去除系统进行降解，从而刺激免疫系统并增强癌细胞的杀伤能力。对于 Mariska 来说，这项活动具有深刻的个人意义，因为她回忆起在她的父亲 Mickey Hargitay 因该疾病去世 20 年后，研究是如何发展的。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260605097757/en/2825504/4/InvestigatingMyeloma_L1058610.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260605097757/en/2825504/4/InvestigatingMyeloma_L1058610.jpg"/></p>
<p>Mariska Hargitay，调查骨髓瘤（照片由 Nikolett Kustos 提供）</p>
<p>“我的父亲曾是并仍然是我的英雄。自从我们失去他于多发性骨髓瘤以来已经过去很多年，但我对这个让我的生活支柱倒下的疾病仍然有很多疑问，” Mariska 说。“这项活动是我向父亲致敬、回答我对骨髓瘤的疑问，并照亮 CELMoD 研究的机会，这是自他去世以来出现的一个了不起的科学研究领域，正在为患者及其亲人带来新的希望。”</p>
<p>Mickey Hargitay 是一位演员、冠军健美运动员和家庭男人。Mariska 第一次注意到在她的婚礼上可能出现了问题，那时 Mickey 总是充满活力，却显得异常疲惫。那时，她认为他只是情绪过于激动，但现在回想起来，她明白那是一个不对劲的信号。忠于他的精神，Mickey 以积极的态度面对他的骨髓瘤诊断，尽管当时的治疗环境与今天大相径庭，他仍然竭尽全力与疾病抗争到最后。她重新连接 Mickey 故事的个人旅程是 “调查骨髓瘤” 的核心，强调了持续科学研究的关键需求。</p>
<p>“听到 Mariska 的故事，我感到一种立即的个人联系。我多年前因多发性骨髓瘤失去了父亲，这段经历继续影响着我在 BMS 的工作方式，” 百时美施贵宝肿瘤商业化高级副总裁 Monica Shaw 博士说。“我曾接受过医学培训，但在他被诊断时我在行业工作，我记得真正理解他的选择和如何获得这些选择是多么困难。没有患者或家庭应该独自应对这种复杂性。这段经历激励我致力于扩大获取途径，简化患者的旅程，并加速对新科学方法的认识——如 CELMoD 研究——这些方法有潜力为多发性骨髓瘤患者带来有意义的改变。”</p>
<p>在超过二十年的开创性研究和开发基础上，BMS 继续推动突破并在疾病连续体中推进护理。BMS 始终致力于患者，正在研究新方法，包括 CELMoD 研究——这是他们更大目标蛋白质降解平台的一部分——以深入了解多发性骨髓瘤复杂的生物学。</p>
<p>“我们对在推进科学以更好地理解多发性骨髓瘤方面的长期承诺和领导地位感到无比自豪。然而，尽管取得了显著进展，改变了这种可治疗但仍无法治愈的疾病，但我们的工作远未结束，” 百时美施贵宝蛋白质稳态主题研究中心高级副总裁 Neil Bence 博士说。“我们创新的 CELMoD 研究是我们对骨髓瘤科学研究的基石。这种方法特别针对细胞自然蛋白质去除系统中的 cereblon，以选择性地降解与该疾病相关的关键蛋白质。”</p>
<p>要了解更多关于 Mariska 的故事以及探索多发性骨髓瘤研究，请访问 InvestigatingMyeloma.com。</p>
<p><strong>关于多发性骨髓瘤</strong></p>
<p>多发性骨髓瘤是一种侵袭性的血癌，起源于骨髓，特别影响浆细胞，这是一种白血球。当浆细胞变得癌变时，它们会失控地增殖，导致各种并发症，包括骨损伤、肾脏问题、免疫功能减弱和贫血。在美国，每年大约有 36,000 个新病例被诊断，它是第二常见的血癌。尽管进展改善了患者的预后，但多发性骨髓瘤仍然无法治愈，其特征是持续的复发循环和逐渐缩短的缓解期，强调了持续研究的关键需求。</p>
<p><strong>关于 CELMoD 研究</strong></p>
<p>百时美施贵宝致力于推进对多发性骨髓瘤的理解和治疗。我们科学研究的一个关键领域是 CELMoD（cereblon E3 连接酶调节）研究，这是一个更大目标蛋白降解平台的一部分。这种创新的方法探讨如何特定地与 cereblon 结合，cereblon 是一种在体内调节细胞蛋白水平的自然过程中的关键蛋白，通过其降解或分解来实现。通过将我们的研究重点放在调节 cereblon 上，百时美施贵宝旨在选择性地与调节多发性骨髓瘤细胞生长和存活的蛋白质结合，具有刺激免疫系统和增强癌细胞杀伤的潜力。这种研究方法强调了我们致力于开辟新的科学途径，以扩展面临这种复杂血癌的患者的可能性。</p>
<p><strong>关于百时美施贵宝：通过科学改变患者生活</strong></p>
<p>在百时美施贵宝，我们的使命是发现、开发和提供创新药物，帮助患者战胜严重疾病。我们正在追求大胆的科学，以定义未来医学和我们服务的患者的可能性。有关更多信息，请访问 BMS.com，并在 LinkedIn、X、YouTube、Facebook 和 Instagram 上关注我们。</p>
<p>corporatefinancial-news</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDUwOTc3NTdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDUwOTc3NTdyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260605097757/en/</p>
<p><strong>百时美施贵宝</strong></p>
<p><strong>媒体咨询：</strong></p>
<p>media@bms.com</p>
<p>来源：百时美施贵宝</p>

百时美施贵宝

<p>百时美施贵宝 (BMY) 与玛丽斯卡·哈吉泰合作推出了 “调查骨髓瘤” 宣传活动，以纪念她的父亲，他在 20 年前因多发性骨髓瘤去世。该活动强调了治疗该疾病的未满足需求，并推广 CELMoD 研究，这是一种由 BMS 主导的靶向蛋白降解方法，旨在增强癌细胞杀伤力并为患者带来新的希望</p>

<p>See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google</p>
<div class="lb-trans"><p>在 Google 搜索和 AI 答案中查看更多来自 StockTitan 的信息。将 StockTitan 添加为首选来源 · 打开 Google</p>
</div><p>Add on Google</p>
<div class="lb-trans"><p>在 Google 上添加</p>
</div><p><strong><em>Multiple myeloma is</em> <em>a complex and incurable blood cancer, characterized by a relentless cycle of relapse and progressively shorter remissions</em></strong></p>
<div class="lb-trans"><p><strong><em>多发性骨髓瘤是一种复杂且无法治愈的血癌，其特征是持续的复发循环和逐渐缩短的缓解期</em></strong></p>
</div><p><strong><em>Campaign highlights unmet needs in myeloma</em> <em>and new science like CELMoD research that is giving patients and their loved ones hope</em></strong></p>
<div class="lb-trans"><p><strong><em>活动突显了多发性骨髓瘤未满足的需求</em> <em>以及像 CELMoD 研究这样的新科学，给患者及其亲人带来了希望</em></strong></p>
</div><p>PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced the launch of “Investigating Myeloma,” a multiple myeloma awareness campaign, in partnership with award-winning actor, director, producer and advocate Mariska Hargitay. This campaign spotlights the importance of ongoing scientific investigation in multiple myeloma, including an approach called CELMoD research led by BMS, defined as cereblon E3 ligase modulation. CELMoD research focuses on engaging key proteins involved in the disease for breakdown by the cell’s own protein removal system to stimulate the immune system and enhance cancer cell killing. For Mariska, this campaign is deeply personal as she reflects on how research has evolved 20 years after her father, Mickey Hargitay, passed away from the disease.</p>
<div class="lb-trans"><p>新泽西州普林斯顿 --（商业资讯）-- 百时美施贵宝（NYSE: BMY）今天宣布与获奖演员、导演、制片人和倡导者 Mariska Hargitay 合作推出 “调查骨髓瘤” 多发性骨髓瘤意识活动。该活动强调了在多发性骨髓瘤中持续科学研究的重要性，包括由 BMS 主导的 CELMoD 研究，这是一种被定义为 cereblon E3 连接酶调节的研究。CELMoD 研究专注于参与疾病的关键蛋白质，以便通过细胞自身的蛋白质去除系统进行降解，从而刺激免疫系统并增强癌细胞的杀伤能力。对于 Mariska 来说，这项活动具有深刻的个人意义，因为她回忆起在她的父亲 Mickey Hargitay 因该疾病去世 20 年后，研究是如何发展的。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mms.businesswire.com/media/20260605097757/en/2825504/4/InvestigatingMyeloma_L1058610.jpg" alt="" original-src="https://mms.businesswire.com/media/20260605097757/en/2825504/4/InvestigatingMyeloma_L1058610.jpg"/></p>
<p>Mariska Hargitay, Investigating Myeloma (Photo by Nikolett Kustos)</p>
<div class="lb-trans"><p>Mariska Hargitay，调查骨髓瘤（照片由 Nikolett Kustos 提供）</p>
</div><p>“My father was and remains my hero. Many years have passed since we lost him to multiple myeloma, but I still have questions about the disease that brought down this pillar in my life,” said Mariska. “This campaign is my chance to honor my dad, answer my questions about myeloma, and shine a light on CELMoD research, a remarkable area of scientific inquiry that has emerged since his death and is renewing hope for patients and their loved ones.”</p>
<div class="lb-trans"><p>“我的父亲曾是并仍然是我的英雄。自从我们失去他于多发性骨髓瘤以来已经过去很多年，但我对这个让我的生活支柱倒下的疾病仍然有很多疑问，” Mariska 说。“这项活动是我向父亲致敬、回答我对骨髓瘤的疑问，并照亮 CELMoD 研究的机会，这是自他去世以来出现的一个了不起的科学研究领域，正在为患者及其亲人带来新的希望。”</p>
</div><p>Mickey Hargitay was an actor, champion body builder and family man. Mariska first noticed something might be wrong at her wedding, where Mickey, always so full of life, seemed unusually tired. At the time, she believed he was just overwhelmed with emotion, but looking back now, understands it was a sign that something wasn’t right. True to his spirit, Mickey approached his myeloma diagnosis with a positive attitude and though the treatment landscape looked different than it does today, he fought with everything he had until the end. Her personal journey of reconnecting with Mickey’s story is at the heart of “Investigating Myeloma, <em>”</em> which underscores the critical need for continued scientific investigation.</p>
<div class="lb-trans"><p>Mickey Hargitay 是一位演员、冠军健美运动员和家庭男人。Mariska 第一次注意到在她的婚礼上可能出现了问题，那时 Mickey 总是充满活力，却显得异常疲惫。那时，她认为他只是情绪过于激动，但现在回想起来，她明白那是一个不对劲的信号。忠于他的精神，Mickey 以积极的态度面对他的骨髓瘤诊断，尽管当时的治疗环境与今天大相径庭，他仍然竭尽全力与疾病抗争到最后。她重新连接 Mickey 故事的个人旅程是 “调查骨髓瘤” 的核心，强调了持续科学研究的关键需求。</p>
</div><p>“Listening to Mariska’s story, I felt an immediate personal connection. I lost my father to multiple myeloma many years ago, and that experience continues to shape how I approach the work we do at BMS,” said Monica Shaw, MD, Senior Vice President, Oncology Commercialization at Bristol Myers Squibb. “I had trained as a physician but was working in industry at the time of his diagnosis, and I remember how difficult it was to truly understand what his options were and how to access them. No patient or family should have to navigate that complexity on their own. That experience fuels my commitment to expanding access, simplifying the journey for patients, and accelerating awareness of new scientific approaches—like CELMoD research—that have the potential to make a meaningful difference for patients living with multiple myeloma.”</p>
<div class="lb-trans"><p>“听到 Mariska 的故事，我感到一种立即的个人联系。我多年前因多发性骨髓瘤失去了父亲，这段经历继续影响着我在 BMS 的工作方式，” 百时美施贵宝肿瘤商业化高级副总裁 Monica Shaw 博士说。“我曾接受过医学培训，但在他被诊断时我在行业工作，我记得真正理解他的选择和如何获得这些选择是多么困难。没有患者或家庭应该独自应对这种复杂性。这段经历激励我致力于扩大获取途径，简化患者的旅程，并加速对新科学方法的认识——如 CELMoD 研究——这些方法有潜力为多发性骨髓瘤患者带来有意义的改变。”</p>
</div><p>Building on more than two decades of pioneering research and development that has transformed the multiple myeloma treatment landscape, BMS continues to drive breakthroughs and advance care across the disease continuum. Guided by an unwavering commitment to patients, BMS is investigating new approaches, including CELMoD research—part of their larger targeted protein degradation platform—to uncover deeper insights into the complex biology of multiple myeloma.</p>
<div class="lb-trans"><p>在超过二十年的开创性研究和开发基础上，BMS 继续推动突破并在疾病连续体中推进护理。BMS 始终致力于患者，正在研究新方法，包括 CELMoD 研究——这是他们更大目标蛋白质降解平台的一部分——以深入了解多发性骨髓瘤复杂的生物学。</p>
</div><p>&#34;We are incredibly proud of our long-standing commitment and leadership in advancing the science to better understand multiple myeloma. However, despite significant progress that has transformed this treatable yet still incurable disease, our work is far from over,&#34; said Neil Bence, PhD, Senior Vice President, Head of Protein Homeostasis Thematic Research Center at Bristol Myers Squibb. &#34;Our innovative CELMoD research is a cornerstone of our scientific investigation into myeloma. This approach specifically engages cereblon within the cell's natural protein removal system to selectively break down key proteins linked to this disease.”</p>
<div class="lb-trans"><p>“我们对在推进科学以更好地理解多发性骨髓瘤方面的长期承诺和领导地位感到无比自豪。然而，尽管取得了显著进展，改变了这种可治疗但仍无法治愈的疾病，但我们的工作远未结束，” 百时美施贵宝蛋白质稳态主题研究中心高级副总裁 Neil Bence 博士说。“我们创新的 CELMoD 研究是我们对骨髓瘤科学研究的基石。这种方法特别针对细胞自然蛋白质去除系统中的 cereblon，以选择性地降解与该疾病相关的关键蛋白质。”</p>
</div><p>To learn more about Mariska’s story and to explore multiple myeloma research, visit InvestigatingMyeloma.com.</p>
<div class="lb-trans"><p>要了解更多关于 Mariska 的故事以及探索多发性骨髓瘤研究，请访问 InvestigatingMyeloma.com。</p>
</div><p><strong>About Multiple Myeloma</strong></p>
<div class="lb-trans"><p><strong>关于多发性骨髓瘤</strong></p>
</div><p>Multiple myeloma is an aggressive blood cancer that begins in the bone marrow, specifically affecting plasma cells, a type of white blood cell. When plasma cells become cancerous, they multiply uncontrollably, leading to various complications including bone damage, kidney problems, weakened immune function, and anemia. With approximately 36,000 new cases diagnosed each year in the U.S., it is the second most common blood cancer. Though advances have improved patient outcomes, multiple myeloma remains incurable and is characterized by a relentless cycle of relapse and progressively shorter remissions, underscoring the critical need for continued research.</p>
<div class="lb-trans"><p>多发性骨髓瘤是一种侵袭性的血癌，起源于骨髓，特别影响浆细胞，这是一种白血球。当浆细胞变得癌变时，它们会失控地增殖，导致各种并发症，包括骨损伤、肾脏问题、免疫功能减弱和贫血。在美国，每年大约有 36,000 个新病例被诊断，它是第二常见的血癌。尽管进展改善了患者的预后，但多发性骨髓瘤仍然无法治愈，其特征是持续的复发循环和逐渐缩短的缓解期，强调了持续研究的关键需求。</p>
</div><p><strong>About CELMoD Research</strong></p>
<div class="lb-trans"><p><strong>关于 CELMoD 研究</strong></p>
</div><p>Bristol Myers Squibb is dedicated to advancing the understanding and treatment of multiple myeloma. A key area of our scientific investigation is CELMoD (cereblon E3 ligase modulation) research, which is one part of a larger targeted protein degradation platform. This innovative approach explores how to specifically engage cereblon, a protein that plays a crucial role within the body’s natural process for regulating the levels of cellular proteins through their degradation, or breakdown. By focusing our research on modulating cereblon, Bristol Myers Squibb aims to selectively engage proteins that regulate the growth and survival of multiple myeloma cells with potential to stimulate the immune system and enhance killing of cancer cells. This research approach underscores our commitment to pioneering new scientific avenues to expand possibilities for patients facing this complex blood cancer.</p>
<div class="lb-trans"><p>百时美施贵宝致力于推进对多发性骨髓瘤的理解和治疗。我们科学研究的一个关键领域是 CELMoD（cereblon E3 连接酶调节）研究，这是一个更大目标蛋白降解平台的一部分。这种创新的方法探讨如何特定地与 cereblon 结合，cereblon 是一种在体内调节细胞蛋白水平的自然过程中的关键蛋白，通过其降解或分解来实现。通过将我们的研究重点放在调节 cereblon 上，百时美施贵宝旨在选择性地与调节多发性骨髓瘤细胞生长和存活的蛋白质结合，具有刺激免疫系统和增强癌细胞杀伤的潜力。这种研究方法强调了我们致力于开辟新的科学途径，以扩展面临这种复杂血癌的患者的可能性。</p>
</div><p><strong>About Bristol Myers Squibb: Transforming Patients’ Lives Through Science</strong></p>
<div class="lb-trans"><p><strong>关于百时美施贵宝：通过科学改变患者生活</strong></p>
</div><p>At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.</p>
<div class="lb-trans"><p>在百时美施贵宝，我们的使命是发现、开发和提供创新药物，帮助患者战胜严重疾病。我们正在追求大胆的科学，以定义未来医学和我们服务的患者的可能性。有关更多信息，请访问 BMS.com，并在 LinkedIn、X、YouTube、Facebook 和 Instagram 上关注我们。</p>
</div><p>corporatefinancial-news</p>
<div class="lb-trans"><p>corporatefinancial-news</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNjA2MDUwOTc3NTdyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260605097757r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20260605097757/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20260605097757/en/</p>
</div><p><strong>Bristol Myers Squibb</strong></p>
<div class="lb-trans"><p><strong>百时美施贵宝</strong></p>
</div><p><strong>Media Inquiries:</strong></p>
<div class="lb-trans"><p><strong>媒体咨询：</strong></p>
</div><p>media@bms.com</p>
<div class="lb-trans"><p>media@bms.com</p>
</div><p>Source: Bristol Myers Squibb</p>
<div class="lb-trans"><p>来源：百时美施贵宝</p>
</div>

Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease | BMY Stock News

Mariska Hargitay 与百时美施贵宝合作开展 “调查骨髓瘤” 宣传活动，以纪念她的父亲在因该疾病去世 20 年后 | 百时美施贵宝股票新闻